LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) stock intrinsic value fair value estimate & owner earnings analysis

Lifecore Biomedical manufactures hyaluronic acid (HA) based injectable and ophthalmic products for other companies under contract - it is a contract development and manufacturing organization (CDMO), not a company selling its own branded drugs. Until 2023 this company was Landec Corporation, a packaged fresh-produce business (Curation Foods, with brands including Eat Smart, Yucatan Guacamole, O Olive and BreatheWay) that also happened to own this HA manufacturing operation. Landec sold the food business in stages through fiscal 2022 and 2023 and renamed itself Lifecore Biomedical to become a pure-play CDMO. Because the businesses were so different, we have valued Lifecore on its performance since that transformation was substantially complete (fiscal years 2024 and 2025, both ended in May); the food-business years and the transition years themselves carry heavy one-time divestiture and refinancing charges that no longer describe the company going forward. Even on this clean, current-business basis, the picture is challenging. Lifecore posted a net loss in both of the last two fiscal years, and once we strip out non-cash items, treat stock-based compensation as a real cost, and account for the capital it needs to spend just to keep its plants running (as opposed to expanding them), its owner earnings were negative in fiscal 2024 (about -$17 million) and negative again in fiscal 2025 (about -$19 million). That is not because operating cash flow itself looked terrible - it was close to breakeven both years - but because the company has been running very high capital spending (10-20% of revenue) to build out manufacturing capacity, while its reported operating cash flow is flattered by a large amount of interest expense that is not actually being paid in cash today. That last point matters a great deal for how we have thought about this company. In May 2023, Lifecore refinanced its bank debt with a $173.5 million term loan from Alcon, which is simultaneously the company's largest customer (44% of fiscal 2025 revenue) and, since that refinancing, its largest lender. The loan carries a 10% interest rate, and almost all of it currently accrues by adding to the loan balance rather than being paid in cash - only about $2 million a year of actual cash interest has been paid recently. Starting in May 2026, a growing portion of that interest converts to a cash obligation, rising through the loan's May 2029 maturity, while the loan balance itself keeps compounding upward in the meantime. On top of that debt, the company has preferred stock outstanding with a redemption value that has already grown past $50 million, accruing at 7.5% a year, which its holders can now demand be redeemed in cash under terms that came into effect in mid-2026. Put simply, Lifecore's balance sheet is highly levered relative to a business that is not yet generating positive owner earnings, and a meaningful part of its recent 'earnings' is really debt growing quietly in the background rather than a cost the company is already paying. We have tried to reflect that reality in our long-term outlook rather than by changing this year's earnings figure - the current losses stay in our numbers as reported, and we assume the company only gradually works its way to sustainable positive owner earnings as its capacity investments mature into volume, while a real share of any improvement gets absorbed by the rising cash cost of its debt. Our base case assumes revenue holds roughly flat to modestly growing in the $125-140 million range over the coming years (Alcon has committed manufacturing capacity from Lifecore through 2033, though it has not guaranteed minimum purchase volumes, so this is not contractually locked in), capital spending gradually normalizes down from its recent elevated levels as the current buildout finishes, and owner earnings improves from roughly -$19 million today to a modestly positive $10-15 million a year by the back half of our outlook. Because Lifecore is unlikely to generate meaningfully positive owner earnings for several years, most of our value estimate rests on what the business is worth a decade and beyond from now, once its capacity investments are finally paying off - that far-out value is inherently less certain than cash flow the company is already producing, and it is the majority of the number we are publishing, so we want to be upfront about that dependence. Our bear case assumes Alcon, which has no obligation to keep buying at current levels, shifts volume elsewhere or that growth from other CDMO customers simply does not materialize, so revenue stalls or declines and owner earnings stays persistently negative. Combined with the mechanically growing debt and preferred stock balances described above, we think there is a real (roughly one-in-ten) chance that Lifecore eventually needs a rescue financing that heavily dilutes or largely wipes out today's shareholders. In that scenario, the company's debt and preferred obligations plausibly exceed what is left over for common shareholders, which is why our bear-case value comes out modestly negative rather than merely low. Our bull case assumes the Alcon relationship expands rather than contracts, other CDMO customers ramp as planned, and the heavy capital spending of the last several years pays off in high-margin, high-utilization manufacturing volume, allowing Lifecore to refinance or pay down its debt from its own growing cash flow instead of needing dilutive rescue capital. Putting this together, our bear case is roughly -$0.50 per share, our base case is roughly $3.70, and our bull case is roughly $13.40. Given how wide that range is, and how much of the downside risk is tied to specific, dated capital-structure events over the next few years rather than to the underlying manufacturing business, the margin-of-safety price is near $1.85 per share, and it assumes the preferred stock situation is resolved without a cash crisis and owner earnings has turned reliably positive for a couple of consecutive quarters, rather than cash flow from operations that owes its recent improvement mainly to interest not yet being paid in cash. A data note: Lifecore's financials were restated more than once during the 2022-2023 divestiture, and we relied on the most recently filed figures throughout. The company also shifted its fiscal year-end from May to December during 2025-2026; we did not have the underlying filing text for that transition report or the most recent quarterly report available to review in full, but the structured financial data from those periods shows revenue decelerating somewhat in the first half of calendar 2026 versus the prior year, alongside operating cash flow returning to a modestly positive level - both of which we treated as informing the shape of our forecast rather than moving the underlying earnings level itself.